V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years

Trial Profile

V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Sponsors Banyu; Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 17 Dec 2009 Actual patient number (100) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual end date (Sept 2009 ) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top